NCT00504400View on ClinicalTrials.gov

Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

September 30, 2009

Conditions
Type 2 Idiopathic Macular Telangiectasia
Interventions
DRUG

Intravitreal injection ranibizumab

Monthly intravitreal injection of of 0.5mg ranibizumab in one eye over one year

Trial Locations (1)

Unknown

Department of Ophthalmology, University of Bonn, Bonn

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University Hospital, Bonn

OTHER